Haloperidol Teva

Haloperidol Teva is a prescription medication that contains the active ingredient haloperidol, a butyrophenone antipsychotic, supplied in oral tablet form. It is marketed in the European Union and is classified under the ATC code N05AD01. As a dopamine D2 receptor antagonist, haloperidol works by modulating neurotransmission in the brain. The product is intended for use under medical supervision and requires a prescription for patients with specific psychiatric conditions.

Haloperidol Teva is indicated for several psychiatric disorders where dopamine blockade is beneficial.

- Management of schizophrenia, including both acute exacerbations and long‑term maintenance therapy. - Treatment of acute psychotic episodes that may occur in the context of mood disorders such as bipolar disorder. - Control of manic episodes in patients with bipolar I disorder when rapid symptom reduction is needed. - Reduction of motor and vocal tics in Tourette syndrome and other tic disorders. - Short‑term control of severe agitation or hostility in hospitalized patients.

Haloperidol Teva may cause a range of adverse effects, which are generally categorized by frequency and clinical significance. The frequency and severity of these events can vary based on dose, treatment duration, and individual patient factors. Patients should be monitored regularly for both common and potentially life‑threatening reactions. Any new or worsening symptom should be reported to a healthcare professional promptly.

Common: - Drowsiness or sedation - Extrapyramidal symptoms such as tremor, rigidity, or akathisia - Dry mouth - Constipation - Blurred vision - Weight gain - Orthostatic hypotension

Serious: - Neuroleptic malignant syndrome - Tardive dyskinesia - Cardiac arrhythmias such as QT prolongation - Seizures - Severe depression or suicidal thoughts - Hepatic dysfunction

When prescribing Haloperidol Teva, clinicians consider several precautionary measures to minimize risk and ensure safe use.

- Assess patient history for cardiovascular disease, especially arrhythmias or prolonged QT interval. - Evaluate for prior extrapyramidal reactions or movement disorders. - Use caution in patients with hepatic or renal impairment; dose adjustments may be required. - Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation. - Consider pregnancy and lactation status; the safety profile is not well established. - Review concomitant medications that may increase the risk of sedation or cardiac effects.

Haloperidol Teva can interact with other medicines, affecting its efficacy or safety profile.

Avoid: - Other dopamine antagonists or antipsychotics (may increase extrapyramidal risk). - Drugs that significantly prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol levels. - Monoamine oxidase inhibitors (MAOIs) – concurrent use may increase risk of severe hypotension. - CYP2D6 substrates that are metabolized by the same pathway (e.g., metoprolol) may have altered plasma levels.

Use with caution: - CNS depressants such as benzodiazepines or opioids (enhanced sedation). - Antihypertensive agents (additive hypotensive effect). - Anticholinergic drugs (may mask extrapyramidal symptoms). - Antidepressants, particularly SSRIs, may alter haloperidol metabolism. - Alcohol consumption can potentiate central nervous system depression.